Compare Stocks: SBTX, ZVRA, CRMD, and PHAT

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRMD CorMedix	$7.19 -3.1%	$7.87	$6.13 ▼ $13.02	$578.35M	1.4	812,982 shs	1.13 million shs
PHAT Phathom Pharmaceuticals	$6.92 -2.3%	$8.68	$6.82 ▼ $18.31	$572.78M	0.5	1.26 million shs	1.68 million shs
SBTX Silverback Therapeutics	$4.07 -1.2%	$5.30	$2.80 ▼ $8.97	$146.76M	0.6	337,931 shs	1.83 million shs
ZVRA Zevra Therapeutics	$9.99 -1.9%	$11.39	$8.01 ▼ $15.03	$593.25M	0.98	915,059 shs	950,608 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRMD CorMedix	-3.10%	-8.41%	-16.49%	-17.83%	-34.93%
PHAT Phathom Pharmaceuticals	-2.26%	-5.21%	-25.27%	-38.21%	-43.69%
SBTX Silverback Therapeutics	-6.36%	-0.72%	-28.60%	-51.87%	-59.00%
ZVRA Zevra Therapeutics	-1.87%	-9.51%	-18.78%	-28.54%	+5.94%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRMD CorMedix	$7.19 -3.1%	$7.87	$6.13 ▼ $13.02	$578.35M	1.4	812,982 shs	1.13 million shs
PHAT Phathom Pharmaceuticals	$6.92 -2.3%	$8.68	$6.82 ▼ $18.31	$572.78M	0.5	1.26 million shs	1.68 million shs
SBTX Silverback Therapeutics	$4.07 -1.2%	$5.30	$2.80 ▼ $8.97	$146.76M	0.6	337,931 shs	1.83 million shs
ZVRA Zevra Therapeutics	$9.99 -1.9%	$11.39	$8.01 ▼ $15.03	$593.25M	0.98	915,059 shs	950,608 shs

7 Energy Stocks to Buy and Hold Forever

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRMD CorMedix	-3.10%	-8.41%	-16.49%	-17.83%	-34.93%
PHAT Phathom Pharmaceuticals	-2.26%	-5.21%	-25.27%	-38.21%	-43.69%
SBTX Silverback Therapeutics	-6.36%	-0.72%	-28.60%	-51.87%	-59.00%
ZVRA Zevra Therapeutics	-1.87%	-9.51%	-18.78%	-28.54%	+5.94%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRMD CorMedix	2.78	Moderate Buy	$15.00	108.62% Upside
PHAT Phathom Pharmaceuticals	2.78	Moderate Buy	$21.25	207.08% Upside
SBTX Silverback Therapeutics	0.00	N/A	N/A	N/A
ZVRA Zevra Therapeutics	3.00	Buy	$27.14	171.70% Upside

Current Analyst Ratings Breakdown

Latest SBTX, ZVRA, CRMD, and PHAT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/23/2026	CRMD CorMedix	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$15.00
9/23/2026	ZVRA Zevra Therapeutics	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
9/9/2026	PHAT Phathom Pharmaceuticals	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Market Perform	$10.00
9/9/2026	PHAT Phathom Pharmaceuticals	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Hold	$10.00
8/20/2026	ZVRA Zevra Therapeutics	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/20/2026	ZVRA Zevra Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$26.00
8/19/2026	ZVRA Zevra Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C)
8/14/2026	PHAT Phathom Pharmaceuticals	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$18.00 ➝ $14.00
8/14/2026	CRMD CorMedix	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$13.00 ➝ $14.00
8/11/2026	CRMD CorMedix	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C)
8/7/2026	ZVRA Zevra Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$24.00 ➝ $23.00

(Data available from 10/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRMD CorMedix	$311.71M	1.80	$1.98 per share	3.63	$5.14 per share	1.40
PHAT Phathom Pharmaceuticals	$239.66M	2.34	N/A	N/A	($6.14) per share	-1.13
SBTX Silverback Therapeutics	N/A	N/A	N/A	N/A	$7.41 per share	N/A
ZVRA Zevra Therapeutics	$136.07M	4.36	$0.93 per share	10.76	$2.75 per share	3.63

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRMD CorMedix	$163.05M	$2.14	3.36	51.36	1.37	40.49%	40.52%	20.61%	11/11/2026 (Estimated)
PHAT Phathom Pharmaceuticals	-$221.25M	-$1.28	N/A	5.97	N/A	-41.34%	N/A	-20.81%	10/29/2026 (Estimated)
SBTX Silverback Therapeutics	-$89.48M	-$2.42	N/A	N/A	N/A	N/A	-29.62%	-28.20%	N/A
ZVRA Zevra Therapeutics	$83.23M	$0.92	10.86	11.89	N/A	42.82%	54.54%	34.15%	11/4/2026 (Estimated)

Latest SBTX, ZVRA, CRMD, and PHAT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
10/29/2026	Q3 2026	PHAT Phathom Pharmaceuticals	$0.07	N/A	N/A	N/A	$85.38 million	N/A
8/13/2026	Q2 2026	CRMD CorMedix	$0.2380	$0.29	+$0.0520	$0.29	$96.04 million	$101.93 million
8/5/2026	Q2 2026	ZVRA Zevra Therapeutics	$0.11	$0.25	+$0.14	$0.14	$33.88 million	$39.66 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRMD CorMedix	N/A	N/A	N/A	N/A	N/A
PHAT Phathom Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SBTX Silverback Therapeutics	N/A	N/A	N/A	N/A	N/A
ZVRA Zevra Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRMD CorMedix	0.31	2.56	2.36
PHAT Phathom Pharmaceuticals	N/A	1.92	1.87
SBTX Silverback Therapeutics	N/A	67.87	67.87
ZVRA Zevra Therapeutics	N/A	5.17	5.12

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRMD CorMedix	34.18%
PHAT Phathom Pharmaceuticals	99.01%
SBTX Silverback Therapeutics	74.89%
ZVRA Zevra Therapeutics	35.03%

Insider Ownership

Company	Insider Ownership
CRMD CorMedix	3.50%
PHAT Phathom Pharmaceuticals	9.33%
SBTX Silverback Therapeutics	34.40%
ZVRA Zevra Therapeutics	3.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRMD CorMedix	191	77.94 million	75.22 million	Optionable
PHAT Phathom Pharmaceuticals	371	80.90 million	73.35 million	Optionable
SBTX Silverback Therapeutics	83	36.06 million	23.65 million	Not Optionable
ZVRA Zevra Therapeutics	61	59.38 million	57.19 million	Optionable

SBTX, ZVRA, CRMD, and PHAT Headlines

Recent News About These Companies

Reviewing Vireo Growth (OTCMKTS:VREOD) & Zevra Therapeutics (NASDAQ:ZVRA)

September 30 at 5:44 AM | americanbankingnews.com

Stock Traders Buy Large Volume of Put Options on Zevra Therapeutics (NASDAQ:ZVRA)

September 25, 2026 | americanbankingnews.com

Stock Traders Buy High Volume of Put Options on Zevra Therapeutics (NASDAQ:ZVRA)

September 24, 2026 | marketbeat.com

Financial Contrast: Zevra Therapeutics (NASDAQ:ZVRA) and Daiichi Sankyo (OTCMKTS:DSNKY)

September 24, 2026 | americanbankingnews.com

Zevra Therapeutics, Inc. (ZVRA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

September 15, 2026 | seekingalpha.com

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Average Rating of "Moderate Buy" by Analysts

September 13, 2026 | marketbeat.com

Bank of America Corp DE Decreases Stock Position in Zevra Therapeutics, Inc. $ZVRA

September 8, 2026 | marketbeat.com

Bank of New York Mellon Corp Invests $2.85 Million in Zevra Therapeutics, Inc. $ZVRA

September 7, 2026 | marketbeat.com

Zevra Therapeutics to Present at Upcoming Investor Conferences

September 2, 2026 | globenewswire.com

Zevra Therapeutics Presents Long-Term Real-World Data Supporting MIPLYFFA in Niemann-Pick Disease Type C at SSIEM Annual Symposium

August 25, 2026 | quiverquant.comQ

Zevra Therapeutics to Present New Long-Term Real-World Data on MIPLYFFA® in Niemann-Pick Disease Type C (NPC) at the 2026 SSIEM Annual Symposium

August 25, 2026 | globenewswire.com

Roth MKM Sticks to Their Buy Rating for Zevra Therapeutics (ZVRA)

August 23, 2026 | theglobeandmail.com

Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

August 21, 2026 | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA

August 13, 2026 | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA

August 11, 2026 | globenewswire.com

What Could Zevra Therapeutics (ZVRA) New NPC Data Mean For Its Europe Review?

August 7, 2026 | finance.yahoo.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA

August 6, 2026 | prnewswire.com

Zevra outlines CHMP reexamination timing with Q4 opinion expected, as MIPLYFFA Orange Book listing extends to 2041

August 6, 2026 | seekingalpha.com

Zevra Therapeutics, Inc. (ZVRA) Q2 2026 Earnings Call Transcript

August 5, 2026 | seekingalpha.com

Zevra Therapeutics (ZVRA) Q2 Earnings and Revenues Surpass Estimates

August 5, 2026 | zacks.com

Zevra Therapeutics (ZVRA) Releases Q2 2026 Earnings: Revenue Growth and EPS Beat

August 5, 2026 | quiverquant.comQ

New MarketBeat Followers Over Time

Media Sentiment Over Time

SBTX, ZVRA, CRMD, and PHAT Company Descriptions

CorMedix NASDAQ:CRMD

$7.19 -0.23 (-3.10%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$7.32 +0.14 (+1.88%)

As of 10/2/2026 07:30 PM Eastern

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.

Phathom Pharmaceuticals NASDAQ:PHAT

$6.92 -0.16 (-2.26%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$7.02 +0.10 (+1.45%)

As of 10/2/2026 07:30 PM Eastern

Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.

Silverback Therapeutics NASDAQ:SBTX

$4.07 -0.05 (-1.21%)

As of 10/2/2026

Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

Zevra Therapeutics NASDAQ:ZVRA

$9.99 -0.19 (-1.87%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$10.00 +0.01 (+0.09%)

As of 10/2/2026 07:55 PM Eastern

Zevra Therapeutics, Inc. discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and Arimoclomol for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SBTX, ZVRA, CRMD, and PHAT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SBTX, ZVRA, CRMD, and PHAT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SBTX, ZVRA, CRMD, and PHAT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SBTX, ZVRA, CRMD, and PHAT Company Descriptions

CorMedix NASDAQ:CRMD

Phathom Pharmaceuticals NASDAQ:PHAT

Silverback Therapeutics NASDAQ:SBTX

Zevra Therapeutics NASDAQ:ZVRA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SBTX, ZVRA, CRMD, and PHAT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SBTX, ZVRA, CRMD, and PHAT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SBTX, ZVRA, CRMD, and PHAT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SBTX, ZVRA, CRMD, and PHAT Company Descriptions

CorMedix NASDAQ:CRMD

Phathom Pharmaceuticals NASDAQ:PHAT

Silverback Therapeutics NASDAQ:SBTX

Zevra Therapeutics NASDAQ:ZVRA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools